R-Pharm operates 11 high-tech manufacturing facilities, each meeting international quality standards. One of the company's key focuses is drug research and development. Today, the group's portfolio includes over 100 proprietary products.

1. "Arcerix" – a medication for the treatment of idiopathic recurrent pericarditis (INN: gofilicept).
2. "Artlegia" – a medication for the treatment of rheumatoid arthritis (INN: olokizumab).

1. "Arcerix"– the first medication in Russia approved for the treatment of idiopathic recurrent pericarditis. This cutting-edge heterodimeric fusion protein exhibits high binding affinity to human interleukins IL-1β and IL-1α. Developed entirely by R-Pharm's in-house laboratories, Arcerix is manufactured domestically at R-Pharm’s state-of-the-art production facilities.

2. "Artlegia" – the world’s first IL-6 inhibitor specifically designed for the treatment of rheumatoid arthritis. Unlike other therapies in this class, Artlegia’s mechanism of action directly targets the cytokine itself rather than its receptor, setting it apart as a highly innovative treatment. It has been incorporated into Russia’s clinical guidelines for rheumatoid arthritis management, the national standard for RA care, COVID-19 treatment protocols, and is listed on the Essential Medicines List (EML). It is produced within Russia at R-Pharm’s facilities.